

SymBio Pharmaceuticals | 4582 |

This PDF document is an updated note on the company. A comprehensive version of the report on the company, including this latest update, is available on our website at <http://www.sharedresearch.jp> and various professional platforms. Our sponsored research reports provide an in-depth and informative view of the companies we cover, and contain the latest available information updated in a timely manner.



On **April 6, 2016**, SymBio Pharmaceuticals announced the issue of a third series unsecured convertible bonds with subscription rights to new shares, and series 39 subscription rights to new shares by third-party allotment.

The company expects to receive total funds of about JPY3.9bn, net of expenses. The company plans to use the funds for expenses related to the development of new drug candidates between April 2016 and December 2018. As of April 6, 2016, SymBio was negotiating license agreements for several new drug candidates with client companies. The amount of funding required is based on costs to acquire rights to new drug candidates or to acquire companies with new drug candidates, as well as estimated developments costs, primarily those required to conduct clinical trials upon acquiring companies with new drug candidates or acquiring rights to new drug candidates.

Overview of the offering

Third series of unsecured convertible bonds with subscription rights to new shares

- ▶ Payment date: April 22, 2016
- ▶ Number of stock subscription rights: 40 units
- ▶ Issue price of bonds: JPY75mn (JPY100 per JPY100 par value)
- ▶ Issue price of stock subscription rights: Gratis
- ▶ Number of potential shares: 14,218,000
- ▶ Total funding amount: JPY3.0bn
- ▶ Conversion price: JPY211
- ▶ Subscription and allocation method: Issued to Whiz Healthcare Japan 2.0 Investment Limited Partnership via third-party allotment.

Series 39 subscription rights to new shares

- ▶ Allotment date: April 22, 2016
- ▶ Number of stock subscription rights: 104 units
- ▶ Issue price: JPY10mn (JPY94,000 per unit)
- ▶ Number of potential shares: 4,472,000
- ▶ Total funding amount: JPY953mn
(JPY10mn from the issue of subscription rights to new shares; JPY944mn from the exercise of subscription rights)
- ▶ Exercise price: JPY211
- ▶ Subscription and allocation method: Issued to Whiz Healthcare Japan 2.0 Investment Limited Partnership via third-party allotment.

This note is the most recent addition to the [full report](#).

About Shared Research Inc.

We offer corporate clients comprehensive report coverage, a service that allows them to better inform investors and other stakeholders by presenting a continuously updated third-party view of business fundamentals, independent of investment biases. Shared Research can be found on the web at <http://www.sharedresearch.jp>.

Disclaimer

This document is provided for informational purposes only. No investment opinion or advice is provided, intended, or solicited. Shared Research Inc. offers no warranty, either expressed or implied, regarding the veracity of data or interpretations of data included in this report. Shared Research Inc. shall not be held responsible for any damage caused by the use of this report.

The copyright of this report and the rights regarding the creation and exploitation of the derivative work of this and other Shared Research Reports belong to Shared Research Inc. This report may be reproduced or modified for personal use; distribution, transfer, or other uses of this report are strictly prohibited and a violation of the copyright of this report. SR Inc. officers and employees may currently, or in the future, have a position in securities of the companies mentioned in this report, which may affect this report's objectivity.

Japanese Financial Instruments and Exchange Law (FIEL) Disclaimer

The report has been prepared by Shared Research Inc. ("SR") under a contract with the company described in this report ("the Company"). Opinions and views presented are SR's where so stated. Such opinions and views attributed to the Company are interpretations made by SR. SR represents that if this report is deemed to include an opinion by SR that could influence investment decisions in the Company, such opinion may be in exchange for consideration or promise of consideration from the Company to SR.

Contact Details

Shared Research.inc

3-31-12 Sendagi Bunkyo-ku Tokyo, Japan

<http://www.sharedresearch.jp>

Phone: +81 (0)3 5834-8787

Email: info@sharedresearch.jp